Survey of healthcare providers' testing practices for vulvovaginal candidiasis and treatment outcomes-United States, 2021

PLoS One. 2022 Dec 30;17(12):e0278630. doi: 10.1371/journal.pone.0278630. eCollection 2022.

Abstract

Vulvovaginal candidiasis (VVC) is a common infection, and high-quality studies report that misdiagnosis is frequent, with diagnostic testing needed to distinguish it from other causes of vaginitis and avoid inappropriate empiric treatment. However, few recent studies have evaluated U.S. healthcare providers' testing practices for VVC in detail. We evaluated healthcare providers' self-reported testing practices for VVC and treatment outcomes as part of a nationwide online survey in order to identify potential opportunities for improving VVC testing and treatment in the United States. Among 1,503 providers surveyed, 21.3% reported "always" (7.4%) or "usually" (13.9%) ordering diagnostic testing for patients with suspected VVC; this proportion was higher among gynecologists (36.0%) compared with family practitioners (17.8%) and internists (15.8%). Most providers (91.2%) reported that patients' VVC "always" (6.4%) or "usually" (84.9%) responds to initial treatment. Whether the symptom resolution reported in this survey was truly related to VVC is unclear given high rates of misdiagnosis and known widespread empiric prescribing. With only about one-in-five providers reporting usually or always performing diagnostic testing for VVC despite guidelines recommending universal use, research is needed to address barriers to proper testing.

MeSH terms

  • Candidiasis, Vulvovaginal* / diagnosis
  • Candidiasis, Vulvovaginal* / drug therapy
  • Female
  • Health Personnel
  • Humans
  • Self-Testing
  • Surveys and Questionnaires
  • Treatment Outcome
  • United States

Grants and funding

The author(s) received no specific funding for this work.